Trials / Terminated
TerminatedNCT05879185
A Study of XmAb23104 in People With Sarcoma
Phase II Study of XmAb23104 (Targeting PD-1 and ICOS), in Patients With Advanced Sarcoma
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to find out whether the study drug, XmAb23104, is an effective treatment for advanced sarcoma. The researchers will also look at whether XmAb23104 is safe and causes few or mild side effects in participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | XmAb23104 | XmAb23104 (10 mg/kg) intravenously on days 1 and 15 of each 28-day cycle. XmAb23104 will be administered by IV infusion at a constant rate over 1 hour. |
Timeline
- Start date
- 2023-04-06
- Primary completion
- 2024-07-19
- Completion
- 2024-07-19
- First posted
- 2023-05-30
- Last updated
- 2026-04-13
- Results posted
- 2026-04-13
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05879185. Inclusion in this directory is not an endorsement.